Loading stock data…
BioVie Inc (BIVI)
$2.01+0.07 (+3.61%)
After Hours$2.04+0.03 (+1.46%)· Last close Jun 29
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioVie Inc. in the Healthcare sector is trading at $2.01 with a market capitalization of $12M. Wall Street consensus targets $5.00 (1 analysts), implying a +148.8% move over the next 12 months. The stock is currently near its 52-week low of $1.06, remaining 33.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +148.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.39M↑ | -$6.26M↓ | -$5.28M↓ | -$3.66M↓ | -$2.99M |
| Net Income | -$5.27M↑ | -$6.07M↓ | -$5.09M↓ | -$3.49M↓ | -$2.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-127.61%
Volume
Today's trading volume
124,428
Recent News
BioVie: Long COVID trial fully enrolled – ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID...
BioVie completes enrollment in Long COVID trial as need for treatments grows
BioVie CEO Cuong Do joined Steve Darling from Proactive to announce the successful completion of patient enrollment for the company’s ADDRESS-LC Phase 2 clinical study evaluating its drug candidate bezisterim for the treatment of neurological symptoms associated with Long COVID. The study marks an important milestone for the company and is fully funded through a grant from the U.S. Department of Defense, helping advance the program without additional financing pressures tied directly to the trial. Do highlighted the growing healthcare challenge posed by Long COVID, which continues to affect millions of individuals long after their initial infection. According to estimates, approximately 15 million adults in the United States reported experiencing Long COVID between 2022 and 2023, with roughly 3.8 million indicating that symptoms significantly interfered with their daily activities and quality of life. The persistence of symptoms has created an increasing need for effective treatment options and greater clinical understanding of the condition. He explained that nearly half of individuals experiencing Long COVID develop symptoms that can persist either continuously or intermittently over extended periods. Among the most common and debilitating complications are neurological symptoms, which often include fatigue, cognitive impairment commonly referred to as “brain fog,” persistent cognitive dysfunction, post-exertional malaise, and sleep disturbances. These symptoms can create significant physical and emotional challenges for patients and have emerged as one of the major areas of focus in Long COVID research. BioVie noted that advancing scientific understanding continues to strengthen the rationale for bezisterim’s proposed mechanism of action. The company believes that growing evidence increasingly points to chronic inflammation and ongoing immune system activity as key contributors to many Long COVID symptoms, particularly those affecting neurological and neuropsychiatric function. Bezisterim is designed to target inflammatory pathways that may be driving these persistent symptoms. Despite growing awareness of Long COVID and increasing research efforts, treatment options remain limited. BioVie emphasized that there are currently no FDA-approved therapies specifically designed to treat Long COVID, leaving a significant unmet medical need and potentially creating a substantial opportunity for therapies capable of addressing the condition effectively. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #ClinicalTrials #Biotech #DrugDevelopment #MedicalResearch #Neurology #HealthcareInnovation #Phase2Trial #Biopharma
BioVie completes enrollment in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the...
BioVie completes final patient visit in Parkinson's drug trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company...
BioVie CEO shares insights into long COVID trial - ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17...